X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2135) 2135
Publication (182) 182
Book Review (17) 17
Newsletter (8) 8
Book Chapter (7) 7
Dissertation (5) 5
Conference Proceeding (3) 3
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1625) 1625
thymidine phosphorylase (973) 973
oncology (720) 720
female (716) 716
thymidine phosphorylase - metabolism (710) 710
animals (587) 587
male (586) 586
index medicus (582) 582
middle aged (480) 480
aged (429) 429
adult (380) 380
cancer (367) 367
expression (329) 329
5-fluorouracil (317) 317
mice (300) 300
prognosis (294) 294
angiogenesis (281) 281
biochemistry & molecular biology (277) 277
thymidine phosphorylase - genetics (261) 261
dihydropyrimidine dehydrogenase (253) 253
thymidine (245) 245
thymidylate synthase (242) 242
immunohistochemistry (238) 238
thymidine - metabolism (237) 237
capecitabine (231) 231
chemotherapy (213) 213
pharmacology & pharmacy (212) 212
cell growth-factor (210) 210
cell line, tumor (189) 189
tumors (189) 189
enzymes (187) 187
carcinoma (181) 181
deoxycytidine - analogs & derivatives (163) 163
aged, 80 and over (162) 162
metastasis (159) 159
colorectal cancer (155) 155
phosphorylase (143) 143
colorectal-cancer (141) 141
fluorouracil (141) 141
fluorouracil - therapeutic use (139) 139
research (138) 138
thymidine kinase - metabolism (138) 138
fluorouracil - analogs & derivatives (137) 137
thymidylate synthase - metabolism (137) 137
fluorouracil - pharmacology (135) 135
mutation (134) 134
antimetabolites, antineoplastic - therapeutic use (133) 133
gene-expression (133) 133
treatment outcome (133) 133
gene expression (130) 130
thymidine phosphorylase - biosynthesis (130) 130
endothelial growth-factor (129) 129
kinetics (129) 129
antineoplastic combined chemotherapy protocols - therapeutic use (126) 126
analysis (124) 124
neoplasm staging (121) 121
tumor angiogenesis (121) 121
tumor cells, cultured (120) 120
breast-cancer (116) 116
thymidine kinase (115) 115
rats (114) 114
apoptosis (110) 110
physiological aspects (110) 110
survival analysis (110) 110
colorectal neoplasms - drug therapy (109) 109
cell biology (108) 108
gene expression regulation, neoplastic (106) 106
antimetabolites, antineoplastic - pharmacology (105) 105
medicine & public health (105) 105
colorectal neoplasms - pathology (103) 103
fluorouracil - metabolism (103) 103
metabolism (103) 103
cell line (102) 102
rna, messenger - metabolism (101) 101
fluorouracil - administration & dosage (100) 100
growth-factor (100) 100
in-vivo (98) 98
thymidine phosphorylase - antagonists & inhibitors (98) 98
care and treatment (97) 97
cells (97) 97
dihydrouracil dehydrogenase - metabolism (96) 96
escherichia-coli (95) 95
reverse transcriptase polymerase chain reaction (95) 95
angiogenic factor (94) 94
medicine, research & experimental (93) 93
neovascularization, pathologic - metabolism (91) 91
pathology (91) 91
genetics & heredity (89) 89
proteins (89) 89
rna, messenger - genetics (89) 89
surgery (89) 89
mice, nude (88) 88
vascular endothelial growth factor a (88) 88
escherichia coli - enzymology (87) 87
antineoplastic agents - pharmacology (86) 86
in-vitro (86) 86
antineoplastic agents - therapeutic use (85) 85
pentosyltransferases - metabolism (84) 84
5'-deoxy-5-fluorouridine (83) 83
dose-response relationship, drug (83) 83
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2089) 2089
Japanese (67) 67
Russian (25) 25
Chinese (23) 23
Polish (5) 5
French (4) 4
Spanish (3) 3
German (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 7/2014, Volume 41, Issue 7, pp. 1327 - 1335
Thymidine phosphorylase (TP), a key enzyme in the pyrimidine nucleoside salvage pathway, catalyses the reversible phosphorylation of thymidine, thereby... 
Medicine & Public Health | Orthopedics | Non-small cell lung cancer | Oncology | [ 18 F]fluorothymidine | Thymidine | Nuclear Medicine | Imaging / Radiology | Cardiology | Positron emission tomography | Thymidine phosphorylase | 3'-DEOXY-3'-FLUOROTHYMIDINE | TUMOR | PROLIFERATION | KINASE-1 ACTIVITY | NUCLEOTIDE | TRANSPORT | [F-18] fluorothymidine | IN-VIVO | GROWTH-FACTOR | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | Dose-Response Relationship, Drug | Time Factors | Pyrrolidines - metabolism | Adult | Female | Biological Transport - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Thymidine Phosphorylase - antagonists & inhibitors | Thymine - metabolism | Thymidine - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Dideoxynucleosides - metabolism | Intracellular Space - drug effects | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - metabolism | Enzyme Inhibitors - pharmacology | Intracellular Space - metabolism | Cell Line, Tumor | Aged | Carcinoma, Non-Small-Cell Lung - enzymology | Thymidine Phosphorylase - metabolism | Phosphates | Enzymes | Analysis | Lung cancer, Small cell | Lung cancer, Non-small cell | Sugars | Monosaccharides | Drug therapy | Patients | Lung cancer | Cells | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, p. e97070
Proangiogenic enzyme thymidine phosphorylase (TP) is a promising target for anticancer therapy, yet its action in non-small cell lung carcinoma (NSCLC) is not... 
IN-VITRO | IL-8 EXPRESSION | A549 CELLS | MULTIDISCIPLINARY SCIENCES | TUMOR-CELLS | PROLIFERATION | HEME OXYGENASE-1 | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | PROMOTES ANGIOGENESIS | MOLECULAR-MECHANISMS | Carcinoma, Non-Small-Cell Lung - pathology | Heme Oxygenase-1 - metabolism | Cell Proliferation | Lung Neoplasms - enzymology | Cytokines - metabolism | Carcinoma, Non-Small-Cell Lung - blood supply | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Gene Expression Regulation, Neoplastic | Neovascularization, Pathologic | Lung Neoplasms - pathology | Animals | NF-E2-Related Factor 2 - metabolism | Cell Line, Tumor | Female | Mice | Carcinoma, Non-Small-Cell Lung - enzymology | Endothelial Cells - pathology | Thymidine Phosphorylase - metabolism | Cell Movement | Lung Neoplasms - blood supply | Antioxidants | Enzymes | Analysis | Acetylcysteine | Lung cancer, Non-small cell | Gene expression | Vascular endothelial growth factor | Cell proliferation | Pediatrics | Biotechnology | Thoracic surgery | Crosstalk | Lung cancer | Thymidine | Biochemistry | Metastasis | Kinases | Drug resistance | Cancer therapies | Cell adhesion & migration | Interleukin 6 | Angiogenesis | Cell growth | Rodents | Heme | NRF2 protein | Interleukin 8 | Squamous cell carcinoma | Small cell lung carcinoma | Cytokines | Heme oxygenase (decyclizing) | Non-small cell lung carcinoma | Lung carcinoma | Inflammation | Biophysics | Phosphorylase | Endothelial cells | Endothelium | Oxygenase | Chemotherapy | Plasmids | Medical prognosis | Polish Americans | Oxygenation | Cell migration | Tumors | Cancer | Endothelial Cells | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Thymidine Phosphorylase | NF-E2-Related Factor 2 | Heme Oxygenase-1
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, p. e96692
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive mitochondrial disease associated with mutations in the nuclear TYMP... 
DNA DEPLETION | MNGIE | MULTIDISCIPLINARY SCIENCES | CELL GROWTH-FACTOR | DISORDER | MODEL | CANCER | EXPRESSION | DELETIONS | TRANSPLANTATION | FEATURES | Immunohistochemistry | Liver - pathology | Muscle, Skeletal - enzymology | Liver - enzymology | Enzyme-Linked Immunosorbent Assay | Humans | Liver - metabolism | Middle Aged | Mitochondrial Encephalomyopathies - genetics | Male | Muscle, Skeletal - metabolism | Duodenum - enzymology | RNA, Messenger - metabolism | Blotting, Western | Mitochondrial Encephalomyopathies - pathology | Duodenum - pathology | Thymidine Phosphorylase - genetics | Duodenum - metabolism | Adult | Female | Muscle, Skeletal - pathology | Thymidine Phosphorylase - metabolism | Enzymes | RNA | Mitochondrial DNA | Gene therapy | Health aspects | Hematopoietic stem cells | Enzyme-linked immunosorbent assay | Enzyme activity | Syngeneic grafts | Liver | Stem cell transplantation | Transplantation | Thymidine | Kinases | Cell growth | Allografts | Enzymatic activity | Bone marrow | Growth factors | Thymidine phosphorylase | Deoxyribonucleic acid--DNA | Life expectancy | Liver diseases | Breast cancer | Gene expression | Patients | Phosphorylase | Hemopoiesis | Quality of life | Neurology | Life span | Hepatocytes | Neurological complications | Stem cells | Glyceraldehyde-3-phosphate dehydrogenase | Nuclei (cytology) | Mutation | Cytoplasm | Liver transplantation | Deoxyribonucleic acid | DNA
Journal Article
Journal of Bacteriology, ISSN 0021-9193, 12/2012, Volume 194, Issue 24, pp. 6847 - 6855
Journal Article
Cancer Science, ISSN 1347-9032, 10/2018, Volume 109, Issue 10, pp. 3294 - 3304
Bevacizumab (Bv) can be used synergistically with fluoropyrimidine‐based chemotherapy to treat colorectal cancer. Whether and how it affects the delivery of... 
bevacizumab | chemosensitization | 5‐fluorouracil | VEGFA/VEGFR2 blockade | thymidine phosphorylase | 5-fluorouracil | ANGIOGENESIS | EFFICACY | DIHYDROPYRIMIDINE DEHYDROGENASE | THYMIDYLATE SYNTHASE | CANCER | VEGFA | CAPECITABINE | PHARMACOKINETICS | ONCOLOGY | VEGFR2 blockade | RESISTANCE | NORMALIZATION | EXPRESSION | Up-Regulation | Bevacizumab - pharmacology | Bevacizumab - therapeutic use | Colonic Neoplasms - drug therapy | Humans | Male | Sp1 Transcription Factor - metabolism | Vascular Endothelial Growth Factor A - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neovascularization, Pathologic - pathology | Vascular Endothelial Growth Factor Receptor-2 - genetics | Fluorouracil - therapeutic use | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - metabolism | Pyridines - therapeutic use | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Neovascularization, Pathologic - drug therapy | Colonic Neoplasms - pathology | Cell Line, Tumor | Fluorouracil - pharmacology | Mice | Mice, Inbred BALB C | Pyridines - pharmacology | Thymidine Phosphorylase - metabolism | Chemotherapy | Colon cancer | Endothelial growth factors | Physiological aspects | Angiogenesis inhibitors | Fluorouracil | Cancer | Drugs | Metabolic rate | Dehydrogenases | Colorectal carcinoma | Colorectal cancer | Cytotoxicity | Drug delivery | Thymidine | Kinases | Cancer therapies | Bevacizumab | Angiogenesis | Metabolites | Paclitaxel | Xenografts | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor | Thymidine phosphorylase | Deoxyribonucleic acid--DNA | Enzymes | MDM2 protein | Statistical analysis | Metabolism | Phosphorylase | Metabolic activation | Antitumor activity | Laboratory animals | Binding sites | Tumors | Original
Journal Article
Orphanet Journal of Rare Diseases, ISSN 1750-1172, 02/2019, Volume 14, Issue 1, pp. 33 - 11
Journal Article